That's why I think Kevetrin is a perfect candidate for combo therapies due it's short half-life and safety profile. Once its MOA is confirmed, we should see more trials involving K.
Quote:The failure of these combo therapies makes me hope that Kevetrin will work by itself, although we know that the company has talked about using it in a combo.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links